• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by PTC Therapeutics Inc.

    4/2/26 3:32:23 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001686217
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    PTC THERAPEUTICS, INC.
    SEC File Number
    001-35969
    Address of Issuer
    500 WARREN CORPORATE CENTER DRIVE
    WARREN
    NEW JERSEY
    07059
    Phone
    9082227000
    Name of Person for Whose Account the Securities are To Be Sold
    Golden Lee Scott
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    82956366.118277473004/02/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/01/2026Restricted Stock VestingIssuerCheckbox not checked82904/01/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Lee S. Golden
    500 Warren Corporate Center Drive
    Warren � NJ � 07059
    Common01/06/20261340103109.78
    Lee S. Golden
    500 Warren Corporate Center Drive
    Warren � NJ � 07059
    Common01/07/202664249744.60
    Lee S. Golden
    500 Warren Corporate Center Drive
    Warren � NJ � 07059
    Common01/08/202686666204.92
    Lee S. Golden
    500 Warren Corporate Center Drive
    Warren � NJ � 07059
    Common02/18/20262484172281.80
    Lee S. Golden
    500 Warren Corporate Center Drive
    Warren � NJ � 07059
    Common03/05/202610000633800.00

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    04/02/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Lee S. Golden.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PTCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    5/27/2026$85.00Hold → Buy
    Jefferies
    5/8/2026$90.00Hold → Buy
    TD Cowen
    4/10/2026$108.00Outperform
    Raymond James
    1/28/2026$119.00Overweight
    Barclays
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    10/20/2025$73.00Overweight
    Wells Fargo
    6/17/2025$80.00Buy
    Truist
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PTC Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded PTC Therapeutics from Hold to Buy and set a new price target of $85.00

    5/27/26 9:06:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics upgraded by TD Cowen with a new price target

    TD Cowen upgraded PTC Therapeutics from Hold to Buy and set a new price target of $90.00

    5/8/26 8:42:12 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on PTC Therapeutics with a new price target

    Raymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00

    4/10/26 8:34:55 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC. VP AND CLO Boulding Mark Elliott sold $202,958 worth of shares (2,812 units at $72.18) as part of a pre-agreed trading plan and exercised 2,812 shares at a strike of $25.69 (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/19/26 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $917,154 worth of shares (12,572 units at $72.95) and was granted 12,500 shares, decreasing direct ownership by 0.02% to 393,998 units (SEC Form 4) to satisfy tax liability

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/15/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXEC. VP AND CLO Boulding Mark Elliott exercised 3,540 shares at a strike of $46.54 and sold $279,570 worth of shares (3,540 units at $78.97) as part of a pre-agreed trading plan (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/12/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    12/14/23 4:38:32 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –   – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback –WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and fi

    5/7/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Participate in Upcoming Investor Conferences

    WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026Tuesday, May 12 at 8:40 a.m. PDT / 11:40 a.m. EDTRBC Capital Markets 2026 Global Healthcare ConferenceWednesday, May 20 at 10 a.m. EDTGoldman Sachs 47th Annual Global Healthcare ConferenceTuesday, June 9 at 9:20 a.m. EDTThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.co

    5/4/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

    - Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a

    4/28/26 4:05:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.

    SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    5/15/26 1:46:16 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PTC Therapeutics Inc.

    10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    5/7/26 4:32:44 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    5/7/26 4:09:45 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PTCT
    Leadership Updates

    Live Leadership Updates

    View All

    PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

    WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise.  "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Ch

    3/25/26 8:30:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

    NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE:IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE:OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.Upwork Inc. (NASD: UPWK) will replace Premier Inc. (NASD: PINC) in the S&P SmallCap 600 effective prior to the open of trading

    11/24/25 6:01:00 PM ET
    $FIBK
    $GIL
    $HBI
    Major Banks
    Finance
    Apparel
    Consumer Discretionary

    $PTCT
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –   – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback –WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and fi

    5/7/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

    - Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a

    4/28/26 4:05:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

    WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. PTC's partner Novartis stated on its quarterly earnings call today that long-term extension data are supportive of the now-initiated Novartis Phase 3 INVEST-HD study and Novartis and PTC will assess potential best next steps for the program including further actions with FDA. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available

    4/28/26 9:28:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/8/24 10:52:39 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    10/18/24 10:57:11 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care